WILMINGTON, Mass., May 19, 2015 /PRNewswire/ -- Implant Sciences
Corporation (OTCQB: IMSC), a leading manufacturer of explosives
trace detection (ETD) and drugs trace detection solutions for
homeland security applications, today announced that it has sold 20
of its QS-B220 desktop explosives trace detectors into Belgium for aviation security. Shipment of
these units is already underway and is expected to be completed,
per customer request, over the next several months.
"Implant Sciences has put an immense amount of effort into its
manufacturing processes and capabilities. We believe that our
ability to date to deliver products when a customer needs it most
has helped us to secure additional wins in Europe, where EU regulations are driving
strict airport procurement and implementation deadlines," stated
Dr. Darryl Jones, Vice President of
Global Sales and Marketing. "We believe that success will breed
success as we hope to continue to capitalize on the significant
opportunities in the region with our best-in-class trace
detectors."
"Implant Sciences' established credibility, due to our superior
performance in both lab and airport operational testing, has given
us significant momentum throughout the ECAC procurements. We
believe we are propelled forward even more so due to word of mouth,
as one EU country is often influenced by a respected neighbor's
buying decision," added Richard
Nelson, Implant Sciences' General Manager of EMEA. "These
frank discussions between security professionals about false alarm
rates and operational readiness of the ETD and their impact on the
bottom line of the airport have, we believe, helped Implant
Sciences further penetrate the EU aviation market."
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 60 countries worldwide. The
Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, CAAC and the
Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the
Interior. It has also received the GSN Homeland Security Award for
"Best Explosives Detection Solution" two years in a row (2013 and
2014). All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees,
representatives and partners of Implant Sciences Corporation (the
"Company") related thereto contain or may contain certain
"forward-looking statements," as that term is defined in the
Private Securities Litigation Reform Act of 1995. Such
statements may include, without limitation, statements with respect
to the Company's plans, objectives, projections, expectations and
intentions and other statements identified by words such as
"projects," "may," "will," "could," "would," "should," "believes,"
"expects," "anticipates," "estimates," "intends," "plans,"
"potential" or similar expressions. Such statements are based
on management's current expectations and are subject to significant
risks and uncertainties (many of which are beyond the Company's
control) that could cause the Company's actual results to differ
materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
there is no guaranty that the Transportation Security
Administration (TSA) or any other U.S. or foreign government and
law enforcement agencies or commercial consumers will purchase any
of our explosives detection products or that any new products we
may develop will be accepted by the TSA or by such other
governments, agencies or consumers; economic, political and other
risks associated with international sales and operations could
adversely affect our sales; our business is subject to intense
competition and rapid technological change, and our ability to
generate revenue and profit will depend on our ability to develop
and introduce new products; and other risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including our most recent Forms 10-K, 10-Q and
8-K. In light of these risks and uncertainties, readers are
cautioned that actual results may differ significantly from those
described or anticipated in the forward-looking statements.
The Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future presentations or otherwise, except as required by applicable
law.
Contact:
Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/another-major-international-european-airport-selects-implant-sciences-qs-b220-300085359.html
SOURCE Implant Sciences Corporation